The median number of BCG doses per patient was 9 in the combination arm and 16 in the monotherapy arm. Phase 3 trial results suggest that adjuvant treatment with mitomycin and bacillus Calmette ...

Investigators presented an interim analysis of the phase 3 ENLIGHTED trial of photodynamic therapy in patients with low-grade upper-tract urothelial cancer.

Health care data breaches that compromised protected health information more than doubled from 2010 to 2024 in the US, data suggest.

The median radiographic progression-free survival was not reached in the niraparib arm and was 29.5 months in the placebo arm. Adding niraparib to abiraterone acetate plus prednisone (AAP) and ...

An artificial intelligence-based tool identifies patients with high-risk, nonmetastatic prostate cancer (PCa) who would most likely benefit from treatment intensification, an investigator reported at ...

The first trial of adjuvant platinum-based chemotherapy plus paclitaxel in patients with high-risk penile cancer provided some insights.

Medical AI tools for clinicians and patients have advantages and disadvantages, including implicit bias in triage and virtual urgent care.

One-year incidence of psychosocial therapy initiation was 12.6 percent, while incidence of medication initiation was 2.8 percent ...

PARP inhibitors demonstrate synergy with radiation, so investigators tested the efficacy and safety of olaparib plus radium-223 in patients with mCRPC and bone metastases in a phase 2 trial.

Protective association seen between GLP-1 receptor agonist use and colon and rectal cancers in adults with obesity and diabetes.

Rapid reduction of glucocorticoid (GC) doses to 7.5 mg/day or less within 6 months may not worsen renal outcomes or increase relapse in patients with proliferative lupus nephritis (LN), recent study ...